SG11202007755YA - Cd83-binding chimeric antigen receptors - Google Patents

Cd83-binding chimeric antigen receptors

Info

Publication number
SG11202007755YA
SG11202007755YA SG11202007755YA SG11202007755YA SG11202007755YA SG 11202007755Y A SG11202007755Y A SG 11202007755YA SG 11202007755Y A SG11202007755Y A SG 11202007755YA SG 11202007755Y A SG11202007755Y A SG 11202007755YA SG 11202007755Y A SG11202007755Y A SG 11202007755YA
Authority
SG
Singapore
Prior art keywords
chimeric antigen
antigen receptors
binding chimeric
binding
receptors
Prior art date
Application number
SG11202007755YA
Other languages
English (en)
Inventor
Marco Davila
Brian Betts
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of SG11202007755YA publication Critical patent/SG11202007755YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202007755YA 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors SG11202007755YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634435P 2018-02-23 2018-02-23
US201862677783P 2018-05-30 2018-05-30
PCT/US2019/019065 WO2019165156A1 (en) 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors

Publications (1)

Publication Number Publication Date
SG11202007755YA true SG11202007755YA (en) 2020-09-29

Family

ID=67686942

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007755YA SG11202007755YA (en) 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors

Country Status (14)

Country Link
US (1) US12492254B2 (enExample)
EP (1) EP3755722A4 (enExample)
JP (1) JP7358369B2 (enExample)
KR (1) KR20200130324A (enExample)
CN (1) CN112004832A (enExample)
AU (1) AU2019226101A1 (enExample)
BR (1) BR112020017015A2 (enExample)
IL (1) IL276836A (enExample)
MA (1) MA51917A (enExample)
MX (1) MX2020008803A (enExample)
PH (1) PH12020500632A1 (enExample)
SG (1) SG11202007755YA (enExample)
WO (1) WO2019165156A1 (enExample)
ZA (1) ZA202005837B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492254B2 (en) 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
JP7701908B2 (ja) * 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
CN114929341A (zh) * 2019-08-16 2022-08-19 H.李.莫菲特癌症中心和研究所股份有限公司 用于治疗髓系恶性肿瘤的嵌合抗原受体
WO2021067290A1 (en) * 2019-09-30 2021-04-08 The Trustees Of The University Of Pennsylvania HUMANIZED ANTI-GDNF FAMILY ALPHA-RECEPTOR 4 (GRF-ALPHA-4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (CARs)
WO2021127212A2 (en) * 2019-12-18 2021-06-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and methods for producing efficacious regulatory t cells
US20230390391A1 (en) * 2020-01-22 2023-12-07 Regents Of The University Of Minnesota Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
US20230107770A1 (en) * 2020-02-20 2023-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
EP4196231A1 (en) * 2020-08-14 2023-06-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Chimeric antigen receptor t cells for treating autoimmunity
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2009155477A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants
US20120177621A1 (en) 2011-01-10 2012-07-12 Samuel Strober Enhancement of Allogeneic Hematopoietic Stem Cell Transplantation
JP2013150592A (ja) * 2011-07-01 2013-08-08 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
PT2951208T (pt) * 2013-02-01 2019-12-30 Univ California Anticorpos anti-cd83 e sua utilização
AU2014223602C1 (en) 2013-02-26 2018-11-08 Axiomx, Inc. Methods for the production of libraries for directed evolution
US9850279B2 (en) 2013-09-13 2017-12-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
CA2965170A1 (en) * 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
JP7372728B2 (ja) 2014-10-31 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改変ｔ細胞に関する方法および組成物
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US20190352409A1 (en) 2016-11-11 2019-11-21 Autolus Limited Chimeric antigen receptor
WO2019051541A1 (en) 2017-09-13 2019-03-21 Dendrocyte Biotech Pty Ltd Treatment method
MX2020002901A (es) 2017-09-19 2020-07-22 Massachusetts Inst Technology Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
AU2018369883A1 (en) 2017-11-15 2020-05-28 Novartis Ag BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
WO2019136335A1 (en) 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
US20200108098A1 (en) 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
US12492254B2 (en) 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
WO2020109953A1 (en) 2018-11-30 2020-06-04 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
JP7701908B2 (ja) 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
WO2021127212A2 (en) 2019-12-18 2021-06-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Systems and methods for producing efficacious regulatory t cells
US20230390391A1 (en) 2020-01-22 2023-12-07 Regents Of The University Of Minnesota Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
WO2023122643A1 (en) 2021-12-22 2023-06-29 Regents Of The University Of Minnesota Cd83 and allo- and autoimmune conditions
JP2024102735A (ja) 2023-01-19 2024-07-31 セイコーエプソン株式会社 頭部装着型表示装置及び光学ユニット

Also Published As

Publication number Publication date
PH12020500632A1 (en) 2021-05-10
CA3092220A1 (en) 2019-08-29
MA51917A (fr) 2021-06-02
US12492254B2 (en) 2025-12-09
EP3755722A4 (en) 2021-11-24
WO2019165156A1 (en) 2019-08-29
MX2020008803A (es) 2021-01-15
JP7358369B2 (ja) 2023-10-10
US20210032336A1 (en) 2021-02-04
BR112020017015A2 (pt) 2020-12-15
KR20200130324A (ko) 2020-11-18
JP2021513857A (ja) 2021-06-03
IL276836A (en) 2020-10-29
ZA202005837B (en) 2023-02-22
CN112004832A (zh) 2020-11-27
EP3755722A1 (en) 2020-12-30
AU2019226101A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
IL276396A (en) Chimeric antigen receptors against CD70
SG11202100205UA (en) Ror-1 specific chimeric antigen receptors and uses thereof
IL277078A (en) Anti-CD33 chimeric antigen receptors and their uses
SG11202102781UA (en) Chimeric antigen receptor
ZA202005837B (en) Cd83-binding chimeric antigen receptors
SG11202010235QA (en) Anti-ror antibody constructs
SG11202100160SA (en) Uses of anti-bcma chimeric antigen receptors
GB201617290D0 (en) Novel chimeric antigen receptors
SG10202108528QA (en) Chimeric antigen receptors targeting flt3
IL279310A (en) CD79A chimeric antigen receptors
EP3134434A4 (en) Kappa/lambda chimeric antigen receptors
GB201807870D0 (en) A CD79-specific chimeric antigen receptor
GB201607968D0 (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
ZA201906321B (en) Chimeric antigen receptor
IL287487A (en) Chemical antigen receptors resistant to rituximab and their uses
GB201709508D0 (en) Chimeric antigen receptor
GB201801831D0 (en) Chimeric receptor
IL287310A (en) Antibodies against 4g7-derived bacterial chemoreceptors
GB201711470D0 (en) Chimeric receptors
GB201807862D0 (en) Chimeric antigen receptor
IL277859A (en) Chimeric NOTCH receptors
GB201721421D0 (en) Chimeric antigen receptor
GB201908239D0 (en) Chimeric antigen receptors
GB201815775D0 (en) Chimeric antigen receptor